Dr. Mårten Steen is a partner at the life sciences venture capital firm HealthCap. Previously, he worked in business development at Merck Serono and has pursued research in the area of blood coagulation at Lund University and Novo Nordisk. Dr. Steen received his Ph.D. in Clinical Chemistry in 2003. He is the author of numerous papers published in peer-reviewed journals and holds a B.Sc. Degree in Business Administration from the Lund University School of Economics and Management.
Dr. Miroslav Reljanović is a medical doctor and a board-certified neurologist. Whilst practicing as a physician in a large WHO Collaborating Centre in Zagreb, he was the clinical investigator in numerous Phase II and III studies in the field of neurology and a consultant to various pharmaceutical companies. In 1997 Miro founded Ergomed and he introduced the novel Study Site Coordination model as an intrinsic part of the conduct of clinical studies. This model became a landmark of the Ergomed approach to clinical research, which is paramount to provide high quality. Miro led Ergomed through a successful IPO on the AIM market of the London Stock Exchange in July 2014 and the subsequent completion of five acquisitions and a secondary offering. Miro transitioned to Executive Vice-Chairman in July 2017 in order to support the Board in growing and developing Ergomed’s CRO offering and to provide strategic guidance on Ergomed’s co-development business and wholly-owned pipeline.
Dr Karin Knobe joined the Board as a Non-executive Director in January 2019. Dr Knobe is currently Head of Rare Blood Disorders Development, Sanofi, Global; and Associate Professor at Lund University. Prior to joining Sanofi, she was Vice President, Head of Clinical Development at Sobi and before that Vice President, Medical and Science, Haemophilia at Novo Nordisk. Dr Knobe is an expert in haemostasis and orphan drug development.
Dr. Torsten Goesch has been the Director of Rosetta Capital secondary life science investments since 2002, where he is responsible for the management of several Rosetta Capital investments and has served on several biotech company boards including Enobia Ltd and Cytochroma Ltd. Dr. Goesch is also founder and former Managing Director of TRG Invest, a Munich-based consulting business providing companies in the life science sector. Additionally, Dr. Goesch served as the General Manager for the German-Speaking Countries at Biogen from 1997-1999, and before that he served as the Commercial Head of Merck KGaA’s worldwide generics drug business Merck Generics. He practiced as a doctor of internal medicine at the University Hospital Hamburg-Eppendorf from 1988-1990, focusing on nephrology, immunology and oncology.
Viktor Drvota is Chief Executive Officer at Karolinska Development. He has more than 13 years of Venture Capital experience with several investments, significant fundraisings, IPOs and exits. He was responsible for the Life Sciences practice at SEB Venture Capital from 2002 to 2016. During his appointment at SEB VC he also served as a board member at several biotech and medtech companies such as Arexis AB, SBL Vaccin AB, Nuevolution AS, Index Pharma AB, Scibase AB, Airsonett AB among others. Before joining SEB, Dr Drvota worked as Senior Consultant and Associate Professor in Cardiology at the Karolinska Institutet/Karolinska University Hospital, Stockholm. He has experience in preclinical and clinical research in drug development and medical devices. Dr. Drvota has contributed as a co-author to 29 research articles.
Professor Mats Wahlgren investigates the molecular pathogenesis of parasitic diseases. Previous positions include directorship of MTC (KI), the Multilateral Initiative on Malaria and the Infection and Vaccinology Programme (SSF). He has been trustee and committee member of the HIV Research Trust, the Wellcome Trust and World Health Organisation. Professor Wahlgren has received a Fogarty Award, the Harford Visiting Professorship at Washington University, the Söderberg professorship of the Royal Swedish Academy of Sciences and a ’Distinguished Professor Award‘ from Karolinska Institutet. He is a member of the Nobel assembly. Professor Wahlgren is co-founder of Modus Therapeutics and several other biotech companies.
Stig Løkke Pedersen was appointed Chairman of the Board in January 2019 and is an experienced life science industry veteran with more than 30 years’ experience. Mr Løkke Pedersen worked for 20 years at H. Lundbeck A/S, and served as the Group’s Chief Commercial Officer between 2005 and 2011. He currently serves as the chairman of the Board in SSI Diagnostica A/S, Moksha8 Ltd, Transmedica A/S and Nuevolution AB. He is a member of the Board in Skybrands A/S, BroenLab A/S and Index Pharmaceuticals AB. Mr Pedersen is also an operating partner in the Danish private equity fund Catacap A/S.